Inhaled immunosuppressant may increase survival, pulmonary function after lung transplant
(University of Maryland Medical Center) University of Maryland School of Medicine researchers found that lung transplant recipients who had early signs of organ rejection could increase their chances of survival by inhaling a liposomal form of the immunosuppression drug cyclosporine through an investigational nebulizer. This is the first randomized, controlled study to demonstrate increased survival and improved lung function with this drug-device combination. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 13, 2019 Category: International Medicine & Public Health Source Type: news
The Impact of NFAT Inhibition on Neutrophil Antifungal Defense and Myelopoiesis in Cyclosporine A Treated and NFATc1LysM Mice
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 20, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Rituximab Noninferior to Cyclosporine in Membranous Nephropathy
WEDNESDAY, July 17, 2019 -- In patients with membranous nephropathy at high risk for progressive disease, rituximab is noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and is superior in maintaining... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 17, 2019 Category: Pharmaceuticals Source Type: news
MENTOR: Rituximab Is a Winner in Membranous Nephropathy MENTOR: Rituximab Is a Winner in Membranous Nephropathy
The anti-CD20 antibody is clearly superior to cyclosporine in inducing, maintaining proteinuria remission in patients with membranous nephropathy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 3, 2019 Category: Consumer Health News Tags: Nephrology News Source Type: news
Medical News Today: What to know about cyclosporine
This article looks at its uses, dosage, side effects, and risks. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 26, 2019 Category: Consumer Health News Tags: Rheumatoid Arthritis Source Type: news
Cyclosporine benefits patients through more rapid remission of proteinuria in lupus nephritis
(European League Against Rheumatism) The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) suggest maintenance therapy with cyclosporine (CYA) results in more rapid remission of proteinuria compared to mycophenolate mofetil (MMF) or azathioprine (AZA) in patients with lupus nephritis. The efficacy of CYA, MMF and AZA in obtaining and maintaining remission of lupus nephritis (LN) is comparable over the long term. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 12, 2019 Category: International Medicine & Public Health Source Type: news
Allergan loses Supreme Court fight to shield Restasis patents with Native American tribe
The U.S. Supreme Court has rejected Allergan ’s attempt to protect drug patents by transferring them a Native American tribe. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 15, 2019 Category: Pharmaceuticals Source Type: news
Breath Therapeutics launches Ph3 trial for inhaled liposomal cyclosporine A therapy
Privately-held Breath Therapeutics said today that it kicked off a Phase III clinical program for its liposomal formulation of cyclosporine A for the treatment of bronchiolitis obliterans syndrome.
The company’s primary drug candidate, L-CsA-i, is an inhaled therapy delivered via Pari Pharma‘s investigational eFlow nebulizer.
Get the full story at our sister site, Drug Delivery Business News.
The post Breath Therapeutics launches Ph3 trial for inhaled liposomal cyclosporine A therapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - March 26, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory breaththerapeutics paripharma Source Type: news
Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome
Phase 3 BOSTON clinical studies will evaluate Liposomal Cyclosporine A for Inhalation (L‑CsA‑i), the first potential therapy for Bronchiolitis Obliterans Syndrome (BOS)
BOS is a devastating lung disease with high mortality affecting over 30,... Biopharmaceuticals Breath Therapeutics, Bronchiolitis Obliterans Syndrome (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 26, 2019 Category: Pharmaceuticals Source Type: news
IVIG Plus Cyclosporine Boosts Heart Outcomes in Resistant Kawasaki Disease IVIG Plus Cyclosporine Boosts Heart Outcomes in Resistant Kawasaki Disease
Adding cyclosporine to intravenous immunoglobulin (IVIG) may prevent adverse coronary artery outcomes in Kawasaki disease patients at risk of not responding to IVIG alone, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 23, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news
Cyclosporine Emulsion Promising in Vernal Keratoconjunctivitis Cyclosporine Emulsion Promising in Vernal Keratoconjunctivitis
Cyclosporine A cationic emulsion (CsA CE) appears more effective than vehicle alone in treating pediatric patients with vernal keratoconjunctivitis, according to a study funded by the developer, Santen.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 17, 2019 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Cequa (Cyclosporine Ophthalmic Solution) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 22, 2018 Category: Drugs & Pharmacology Source Type: news
FDA Clears New Treatment for Dry Eye (Cequa) FDA Clears New Treatment for Dry Eye (Cequa)
Cequa is a patented, novel, proprietary nanomicellar formulation of cyclosporine A in a clear, preservative-free, aqueous solution.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 17, 2018 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news
Sun Pharma Announces FDA Approval of Cequa (cyclosporine) Ophthalmic Solution to Treat Dry Eye Disease
MUMBAI, India& PRINCETON, N.J.--(BUSINESS WIRE)-- August 16, 2018 -- Sun Pharmaceutical Industries Ltd. (Reuters:SUN.BO, Bloomberg:SUNP IN, NSE:SUNPHARMA, BSE:524715, “Sun Pharma” and includes its subsidiaries and/or associate companies)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 16, 2018 Category: Drugs & Pharmacology Source Type: news
Sun Pharma receives USFDA nod ophthalmic solution used to treat dry eye disease
New Delhi, Aug 16 () Sun Pharma has received approval from the US health regulator for CEQUA (cyclosporine ophthalmic solution), used to increase tear production in patients with keratoconjunctivitis sicca (dry eye). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 16, 2018 Category: Pharmaceuticals Source Type: news
